New drug cocktail aims to shrink kidney tumors before surgery
NCT ID NCT07593040
First seen May 21, 2026 · Last updated May 21, 2026
Summary
This study tests whether giving a combination of three drugs (pembrolizumab, belzutifan, and lenvatinib) before surgery can shrink kidney tumors in people with localized clear cell renal cell carcinoma. About 150 participants will receive the drugs for 12 weeks, then have surgery, followed by more immunotherapy. The goal is to see if this approach reduces tumor size more effectively than standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Complejo Hospitalario Universitario De Ourense
Ourense, Galicia, 32005, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital Clinic De Barcelona
Barcelona, Catalonia, 08036, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital Clinico Universitario Lozano Blesa
Zaragoza, Aragon, 50009, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital Universitari Vall D Hebron
Barcelona, Catalonia, 08035, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital Universitario 12 De Octubre
Madrid, Madrid, 28041, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital Universitario Central De Asturias
Oviedo, Principality of Asturias, 33011, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital Universitario De Navarra
Pamplona, Navarre, 31008, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital Universitario Lucus Augusti
Lugo, Galicia, 27003, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital Universitario Marques De Valdecilla
Santander, Cantabria, 39008, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital Universitario Ramon Y Cajal
Madrid, Madrid, 28034, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital Universitario Reina Sofia
Córdoba, Andalusia, 14004, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hospital Universitario Y Politecnico La Fe
Valencia, Valencia, 46026, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Institut Catala D'oncologia
L'Hospitalet de Llobregat, Catalonia, 08908, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Parc Tauli Hospital Universitari
Sabadell, Catalonia, 08208, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.